uniQure (NASDAQ:QURE) Announces Earnings Results, Misses Estimates By $0.40 EPS

Posted by Stanley Muller on Jul 29th, 2026

uniQure (NASDAQ:QURE – Get Free Report) posted its quarterly earnings results on Wednesday. The biotechnology company reported ($1.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.40), FiscalAI reports. The business had revenue of $5.84 million for the quarter, compared to the consensus estimate of $5.45 million. uniQure had a negative return on equity of 145.81% and a negative net margin of 1,154.42%.During the same quarter in the previous year, the business posted ($0.69) EPS.

Here are the key takeaways from uniQure’s conference call:

AMT-130 remains on track for a U.S. BLA submission in the third quarter under the FDA’s Accelerated Approval pathway, with three-year Phase I/II data accepted as the primary basis. A U.K. submission to the MHRA is also planned for the third quarter.
The FDA indicated that a confirmatory study may use a randomized standard-of-care control rather than a sham procedure, potentially simplifying execution. uniQure expects to align on the design and begin a global study promptly, with Total Functional Capacity at 36 months under consideration as the primary endpoint.
uniQure expects to present four-year AMT-130 data in September, including safety, tolerability, functional outcomes, natural-history comparisons and CSF neurofilament light data. Management is in a quiet period and declined to provide additional commentary on the results ahead of the readout.
Early AMT-260 epilepsy data showed seizure reductions of 79% to 100% below baseline in three of six low-dose patients, but outcomes varied widely among the remaining participants; higher-dose enrollment is nearly complete. AMT-191 produced dose-dependent enzyme activity increases in all 11 patients, although two grade 3 liver-enzyme events paused further mid- and high-dose dosing pending FDA agreement on monitoring.
Cash, cash equivalents and investments totaled $810.3 million at quarter-end, up from $622.5 million at year-end 2025, and management expects the balance sheet to fund operations, the confirmatory trial, potential AMT-130 launches and ongoing development into 2030.

uniQure Stock Performance

uniQure stock traded up $3.46 during midday trading on Wednesday, hitting $40.12. The company’s stock had a trading volume of 1,825,196 shares, compared to its average volume of 2,568,996. The company has a 50-day moving average price of $36.44 and a two-hundred day moving average price of $25.89. uniQure has a 1-year low of $8.73 and a 1-year high of $71.50. The company has a market cap of $2.53 billion, a price-to-earnings ratio of -11.49 and a beta of 0.90. The company has a debt-to-equity ratio of 0.33, a current ratio of 10.40 and a quick ratio of 10.40.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of uniQure in a research report on Friday, June 26th. Leerink Partners increased their price target on uniQure from $36.00 to $70.00 and gave the company an “outperform” rating in a research note on Thursday, June 18th. Chardan Capital lifted their price objective on shares of uniQure from $31.00 to $37.00 and gave the stock a “buy” rating in a research report on Thursday, April 30th. Royal Bank Of Canada raised their target price on shares of uniQure from $35.00 to $65.00 and gave the stock an “outperform” rating in a research note on Thursday, June 18th. Finally, Barclays upgraded shares of uniQure from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $25.00 to $65.00 in a research report on Thursday, June 18th. Twelve equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $64.17.

Read Our Latest Research Report on uniQure

Insider Transactions at uniQure

In related news, Director Jack Kaye sold 21,167 shares of the business’s stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $46.44, for a total value of $982,995.48. Following the completion of the transaction, the director owned 25,996 shares of the company’s stock, valued at $1,207,254.24. The trade was a 44.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Walid Abi-Saab sold 45,000 shares of the company’s stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $25.06, for a total transaction of $1,127,700.00. Following the sale, the insider directly owned 169,669 shares of the company’s stock, valued at $4,251,905.14. This represents a 20.96% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 433,229 shares of company stock worth $17,944,799. Corporate insiders own 4.65% of the company’s stock.

Hedge Funds Weigh In On uniQure

Several hedge funds have recently bought and sold shares of QURE. Virtus Investment Advisers LLC lifted its holdings in shares of uniQure by 91.6% during the 4th quarter. Virtus Investment Advisers LLC now owns 13,636 shares of the biotechnology company’s stock worth $326,000 after acquiring an additional 6,520 shares during the period. SummitTX Capital L.P. increased its stake in uniQure by 386.3% in the fourth quarter. SummitTX Capital L.P. now owns 27,708 shares of the biotechnology company’s stock valued at $663,000 after acquiring an additional 22,010 shares during the last quarter. Suvretta Capital Management LLC acquired a new position in uniQure during the fourth quarter valued at approximately $29,116,000. Readystate Asset Management LP bought a new stake in uniQure during the fourth quarter worth $8,652,000. Finally, Orbimed Advisors LLC lifted its stake in uniQure by 60.8% during the fourth quarter. Orbimed Advisors LLC now owns 737,400 shares of the biotechnology company’s stock worth $17,646,000 after purchasing an additional 278,900 shares during the last quarter. 78.83% of the stock is owned by institutional investors.

uniQure Company Profile

(Get Free Report)

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.